Seeking Alpha


Send Message
View as an RSS Feed
View dow43's Comments BY TICKER:
Latest  |  Highest rated
  • Expected FDA ruling on neostigmine fuels Flamel's uptrend [View news story]
    When could we expect a final decision from FDA about exclusivity to Eclat ?
    Jun 23 09:21 AM | Likes Like |Link to Comment
  • Why I Think Relypsa Is Overvalued By $400M [View article]
    ZS Pharma is a small Texan based 5 people start-up with no partner on hand for marketing-this is no competitor.
    Kayexalate has serious side effects and only used for acute hyperkalemia. Right now there is no drug to treat this condition long term. Do you know a price level for this drug and if they want to launch ex-US? Thx Dow
    Dec 19 08:02 AM | Likes Like |Link to Comment
  • After A Big Rally, What Propels Lonza Now? [View article]
    Thank you Stephen for the article. How do you see the future of Lonza┬┤s small molecule business?
    Dec 12 05:45 PM | Likes Like |Link to Comment
  • MannKind's Steady Progression Towards FDA Approval Continues Unabated [View article]
    Ok if you look really close in the phase 3 results posted by Mannkind you will see a lot of questionmarks:
    For Typ 1 diab they did not achieve HBA1c & for T2DM a weight gain was associated and much more hypos were reported. For me the data are maybe enough to get approval but an early usage in diabetes of the product is doubtfull.
    Aug 21 09:39 AM | Likes Like |Link to Comment
  • Teva (TEVA -0.6%) and Lonza (LZAGY.PK -5.8%) mutually agree to terminate their biosimilars collaboration following a strategic review. TEVA will continue to pursue its biologics strategy while Lonza will focus on its core competencies including contract manufacturing and cell line development. (PR[View news story]
    when they bought Celerant and ratiopharm!
    Jul 25 09:42 PM | Likes Like |Link to Comment